FDA-Approved Kidney Drug Sevelamer Shows Promise in Fighting Antibiotic Resistance
• Penn State researchers have demonstrated that sevelamer, an FDA-approved dialysis drug, can capture "off-target" antibiotics in the gut, potentially preventing bacteria from developing resistance.
• The drug successfully bound vancomycin and daptomycin—two commonly prescribed antibiotics—in mouse models, blocking antibiotic activity and preventing resistance evolution in gut bacteria.
• As 5-10% of intravenously administered antibiotics end up in the gastrointestinal tract where bacteria can develop resistance, this "anti-antibiotic" approach offers a novel strategy to preserve antibiotic effectiveness.
Beyond Obesity: GLP-1 Drugs Show Promise in Addiction, Neurodegeneration, and More
• GLP-1 receptor agonists, initially developed for weight loss, are being investigated for their potential to curb cravings and addictions, including alcohol and tobacco use.
• Clinical trials suggest GLP-1 drugs may reduce the risk of cardiovascular events and kidney complications, potentially through mechanisms beyond weight loss, such as reducing inflammation.
• Research indicates GLP-1 drugs could ease symptoms of neurodegenerative diseases like Parkinson's and Alzheimer's by reducing brain inflammation and improving mitochondrial function.
• Studies are exploring the use of GLP-1 medications for various conditions, including depression, anxiety, and even fertility issues, highlighting the broad impact of these drugs.
NIH Funds Development of Decision Aid for Early Deep Brain Stimulation in Parkinson's Disease
• A $1.5 million NIH grant supports the development of a patient-centered decision aid for early Deep Brain Stimulation (DBS) consideration in Parkinson's disease.
• The decision aid aims to facilitate shared decision-making between patients, clinicians, and caregivers regarding DBS treatment.
• The tool will address ethical concerns and individual preferences to determine the most appropriate timing for DBS intervention.
• Researchers hope the decision aid will promote responsible use of neurotechnologies for various brain disorders beyond Parkinson's.
© Copyright 2025. All Rights Reserved by MedPath